Who are MCT/LCT (1:1)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MCT/LCT/omega-3 (5:4:1), ClinOleic, ClinOleic (baseline), Lipoplus 20%, Lipofundin MCT, SMOFlipid (baseline).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mct-lct-1-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

MCT/LCT (1:1) — Competitive Intelligence Brief

MCT/LCT (1:1) (MCT/LCT (1:1)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipid emulsion for parenteral nutrition. Area: Nutrition support.

marketed Lipid emulsion for parenteral nutrition Nutrition support Small molecule Live · refreshed every 30 min

Target snapshot

MCT/LCT (1:1) (MCT/LCT (1:1)) — B. Braun Medical SA. MCT/LCT (1:1) is a lipid emulsion that provides a balanced mixture of medium-chain triglycerides and long-chain triglycerides for parenteral nutrition.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
MCT/LCT (1:1) TARGET	MCT/LCT (1:1)	B. Braun Medical SA	marketed	Lipid emulsion for parenteral nutrition
MCT/LCT/omega-3 (5:4:1)	MCT/LCT/omega-3 (5:4:1)	B. Braun Medical SA	marketed	Lipid emulsion for parenteral nutrition
ClinOleic	ClinOleic	Shanghai Jiao Tong University School of Medicine	marketed	Lipid emulsion for parenteral nutrition
ClinOleic (baseline)	ClinOleic (baseline)	General University Hospital, Prague	marketed	Lipid emulsion for parenteral nutrition
Lipoplus 20%	Lipoplus 20%	B. Braun Melsungen AG	marketed	Lipid emulsion for parenteral nutrition
Lipofundin MCT	Lipofundin MCT	B. Braun Melsungen AG	marketed	Lipid emulsion for parenteral nutrition
SMOFlipid (baseline)	SMOFlipid (baseline)	General University Hospital, Prague	marketed	Lipid emulsion for parenteral nutrition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipid emulsion for parenteral nutrition class)

B. Braun Melsungen AG · 3 drugs in this class
B. Braun Medical SA · 2 drugs in this class
General University Hospital, Prague · 2 drugs in this class
Shanghai Jiao Tong University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MCT/LCT (1:1) — Competitive Intelligence Brief. https://druglandscape.com/ci/mct-lct-1-1. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab